Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $230.15 USD
Updated Mar 30 1:25pm
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VRTX Stock Summary
- VRTX has a market capitalization of $57,850,601,156 -- more than approximately 97.71% of US stocks.
- Price to trailing twelve month operating cash flow for VRTX is currently 36.86, higher than 93.73% of US stocks with positive operating cash flow.
- With a price/sales ratio of 13.9, Vertex Pharmaceuticals Inc has a higher such ratio than 93.45% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Vertex Pharmaceuticals Inc, a group of peers worth examining would be QCOM, AMAT, REGN, MU, and AMD.
- Visit VRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.vrtx.com.
VRTX Stock Price Chart More Charts
VRTX Price/Volume Stats
| Current price | $230.15 | 52-week high | $249.85 |
| Prev. close | $217.24 | 52-week low | $163.68 |
| Day low | $220.00 | Volume | 870,083 |
| Day high | $233.77 | Avg. volume | 1,805,990 |
| 50-day MA | $229.60 | Dividend yield | N/A |
| 200-day MA | $201.13 | Market Cap | 59.67B |
Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $230.15 | $31889.51 | 14579% |
Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 97th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 14651.17%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:
- In the past 3.29 years, Vertex Pharmaceuticals Inc has a compound free cash flow growth rate of 2.66%; that's higher than 96.84% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.32% of the free cash flow producing stocks we're observing.
- VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 61.83% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 14292% |
| 1% | 14435% |
| 2% | 14579% |
| 3% | 14723% |
| 4% | 14867% |
| 5% | 15011% |
Want more companies with a valuation profile/forecast similar to that of Vertex Pharmaceuticals Inc? See NVCR, DRRX, ASRT, RDY, and FVE.
Top Stories View All
An Update on CannTrust (CTST) as it Awaits Crucial News from Health Cananda
2 Companies That are Bucking the Trend in the Stock Market
Top 4 Home Improvement Stocks with Stimulus Checks on the Way
Rip Your Face Off Rally!
Best & Worst Performing Stock Industries for March 27, 2020
View All Top Stories
Loading social stream, please wait...